A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
Recruiting · Phase 1 · NCT07219030
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $79,569
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 52
About the trial
- Sponsor
- AbbVie
- Tested
- Emraclidine (drug), Placebo (drug)
- Dates
- Started 2025-10-08; completion 2026-12
- Results posted
- Not yet
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
From ClinicalTrials.gov, last updated 2026-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $79,569 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Esteban Olivera, MD Emergency Medicine · Kissimmee, FL
- Alexander N. Prezioso, M.D. Specialist · Lake Hopatcong, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Erg Holding Company LLC $55,569
- K2 Medical Research LLC $24,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.